This medication is given by IV infusion.
Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in MS, it was used only to treat certain forms of cancer. It acts in MS by suppressing the activity of T cells, B cells, and macrophages that are thought to lead the attack on the myelin sheath.
The U.S. Food and Drug Administration (FDA) has approved Novantrone for reducing neurologic disability and/or the frequency of clinical relapses (attacks) in:
- secondary progressive MS (disease that has changed from relapsing-remitting to progressive at a variable rate);
- progressive-relapsing MS (disease characterized by gradual increase in disability from onset with clear, acute relapses along the way);
- worsening relapsing-remitting MS (disease characterized by clinical attacks without complete remission, resulting in a step-wise worsening of disability.
Note: Novantrone has not been approved for the treatment of primary-progressive MS (characterized by progression from disease onset with no acute attacks or remissions).
Click here to read the Novantrone Prescribing Information for healthcare professionals.
Click here and scroll to p. 36 to read the Novantrone Medication Guide for patients.
None available at this time.
Financial Assistance Program
No patient assistance program available at this time.